• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    9/29/23 5:31:37 PM ET
    $BNOX
    $CMRA
    $GRI
    $HSCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BNOX alert in real time by email

    Gainers

    • Bionomics (NASDAQ:BNOX) stock moved upwards by 24.0% to $3.46 during Friday's after-market session. Today's trading volume for this security ended up closing at 1.8 million shares, which is 85.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $28.2 million.
    • Oragenics (AMEX:OGEN) shares increased by 21.54% to $3.61. This security traded at a volume of 308.9K shares come close, making up 2992.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $9.1 million.
    • Syndax Pharmaceuticals (NASDAQ:SNDX) stock moved upwards by 15.15% to $16.72. Trading volume for this security closed at 79.2K, accounting for 10.0% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 billion.
    • GRI Bio (NASDAQ:GRI) shares rose 12.25% to $1.74. The market value of their outstanding shares is at $5.1 million.
    • TRACON Pharma (NASDAQ:TCON) stock moved upwards by 9.55% to $0.2. The company's market cap stands at $5.9 million.
    • Senti Biosciences (NASDAQ:SNTI) stock increased by 8.97% to $0.46. The market value of their outstanding shares is at $20.6 million.

    Losers

    • Comera Life Sciences (NASDAQ:CMRA) stock decreased by 12.3% to $0.28 during Friday's after-market session. The company's market cap stands at $8.6 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock fell 6.98% to $0.4. This security traded at a volume of 74.9K shares come close, making up 11.8% of its average volume over the last 100 days. The company's market cap stands at $2.9 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares decreased by 5.73% to $0.82. The company's market cap stands at $3.0 million.
    • Heart Test Laboratories (NASDAQ:HSCS) shares decreased by 5.34% to $0.41. The market value of their outstanding shares is at $4.4 million.
    • Plus Therapeutics (NASDAQ:PSTV) stock declined by 5.23% to $1.27. The market value of their outstanding shares is at $3.6 million.
    • Tenax Therapeutics (NASDAQ:TENX) stock decreased by 5.03% to $0.28. The company's market cap stands at $6.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BNOX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNOX
    $CMRA
    $GRI
    $HSCS

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Syndax Pharmaceuticals Inc.
    $SNDX
    10/16/2025$40.00Buy
    H.C. Wainwright
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    Syndax Pharmaceuticals Inc.
    $SNDX
    9/10/2025$44.00Buy
    Stifel
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Syndax Pharmaceuticals Inc.
    $SNDX
    9/4/2025$34.00Buy
    Guggenheim
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    More analyst ratings

    $BNOX
    $CMRA
    $GRI
    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 10,757 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:55 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO Lu Timothy K covered exercise/tax liability with 80,666 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    3/11/26 4:01:30 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Sims Andrew John Hugh Macintyre

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    2/27/26 4:08:43 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $BNOX
    $CMRA
    $GRI
    $HSCS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

    Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

    11/18/24 9:22:42 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNOX
    $CMRA
    $GRI
    $HSCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright resumed coverage on Syndax Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    10/16/25 8:20:22 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNOX
    $CMRA
    $GRI
    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights. "2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENT

    3/27/26 8:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

    HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. "Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his bre

    3/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

    SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on March 16, 2026 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 to the Company's

    3/25/26 6:30:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNOX
    $CMRA
    $GRI
    $HSCS
    SEC Filings

    View All

    $BNOX
    $CMRA
    $GRI
    $HSCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.

    SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)

    3/27/26 1:15:55 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Senti Biosciences Inc.

    10-K - Senti Biosciences, Inc. (0001854270) (Filer)

    3/27/26 8:06:56 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    3/27/26 8:01:49 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNOX
    $CMRA
    $GRI
    $HSCS
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

    HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. "Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his bre

    3/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

    Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Recent accomplishments include expansion of the CNSide manufacturing footprint,

    10/21/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

    - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa

    5/12/25 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNOX
    $CMRA
    $GRI
    $HSCS
    Financials

    Live finance-specific insights

    View All

    Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2025 and full year 2025 and provided a summary of recent pipeline and corporate highlights. "2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENT

    3/27/26 8:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

    SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California. The presentations will include data from the ongoing Phase I clinical trial of SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing he

    3/23/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

    HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid (CSF) assay. The cost-of-care analysis suggests that earlier LM diagnosis and therapeutic management enabled by CNSide may reduce overall LM-related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention, improved treatment precisio

    3/19/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $BNOX
    $CMRA
    $GRI
    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care